Fizzah Ikram Ul Haq

Ms. Fizzah Ikram Ul Haq

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2025 in Journal of the Pakistan Medical Association
Verified
Journal Article
Open access
PDF file
FHFizzah Ikram Ul Haq
Fizzah Ikram Ul Haq
AHAaitain Ikram Ul Haq
Aaitain Ikram Ul Haq
Dear Editor, Type 2 diabetes or (T2D) is characterized by the elevated blood glucose levels resulting from impaired beta-cell function and insulin resistance. According to the International Diabetes Federation (IDF), 1 in 10 people globally suffer from diabetes mellitus. The comparative adult prevalence rate of diabetes mellitus in Pakistan is estimated to be 30.8 % (1). One of the most prevalent complications of Type 2 Diabetes is chronic kidney disease (CKD). CKD is estimated to affect 50% of the population suffering from T2D (2). Traditionally, RAAS and SGLT-2 inhibitors are used as interventions to decline the progression of CKD. While effective, a novel therapeutic option, finerenone, has recently emerged as a breakthrough in improving both renal and cardiovascular outcomes in patients with CKD and T2D (3). Finerenone is a non-steroidal mineralocorticoid receptor antagonist that selectively inhibits aldosterone’s effects at its receptor. Unlike steroidal mineralocorticoid receptor antagonists (MRAs) such as spironolactone and eplerenone, finerenone offers significant renal protection without causing substantial elevations in serum potassium levels (4). Clinical trials have demonstrated that finerenone significantly reduces the urine albumin-to-creatinine ratio, slows estimated glomerular filtration rate (eGFR) decline, and mitigates progression to end-stage renal disease (5). Furthermore, finerenone does not cause significant rise in serum potassium levels which is a major side effect of steroidal mineralocorticoid receptor antagonists i.e. spironolactone and eplerenone. Thus, finerenone has almost the same effect along with a lower risk of hyperkalaemia as compared to that of steroidal mineralocorticoid receptor antagonists (4). Moreover, the lower risk of hyperkalaemia associated with finerenone makes it a safer alternative for long-term use. The drug’s beneficial effects in combination with RAAS and SGLT-2 inhibitors are now reflected in international treatment guidelines for CKD management in patients with T2D (3). With the recent availability of finerenone in Pakistan, it is the need of the hour to spread the word about this ground breaking drug and revise guidelines across urban and rural health care settings of Pakistan so that mortality and morbidity can be reduced amongst patients with CKD in T2D. Through these steps, the disease burden of end stage kidney failure amongst T2D patients in Pakistan can be reduced eventually.

13 August 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
HAHassaan Abid
Hassaan Abid
GLGovinda Lohano
Govinda Lohano
BKBhawan Kumar
Bhawan Kumar
KIKinza Irshad
Kinza Irshad
GLGaaitri Lohano
Gaaitri Lohano
MHMoiz Ul Haq Hashmi
Moiz Ul Haq Hashmi
Background/Objectives: Cardiac arrest and fluid, electrolyte, and acid–base disorders frequently coexist in critically ill patients and are associated with poor clinical outcomes. However, long-term population-level trends in mortality involving both conditions remain poorly characterized. This study evaluated temporal trends and demographic disparities in mortality involving cardiac arrest and fluid, electrolyte, and acid–base disorders among U.S. adults from 2004 to 2024. Methods: We conducted a retrospective population-based study using the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) Multiple Cause of Death database. Adults aged ≥25 years with cardiac arrest (ICD-10: I46) and fluid, electrolyte, and acid–base disorders (ICD-10: E87) listed anywhere on the same death certificate between 2004 and 2024 were included. Age-adjusted mortality rates (AAMRs) were calculated using the 2000 U.S. standard population. Joinpoint regression was used to estimate annual percent change (APC) and average annual percent change (AAPC), with analyses stratified by demographic and geographic characteristics. Results: A total of 152,937 deaths involved both cardiac arrest and fluid, electrolyte, and acid–base disorders during the study period. The AAMR nearly doubled, increasing from 2.06 (95% CI, 2.00–2.13) in 2004 to 4.08 (95% CI, 4.00–4.16) in 2024, corresponding to an overall AAPC of 3.42% (95% CI, 2.58–4.26; p < 0.001). Mortality remained consistently higher among males, adults aged ≥65 years, and non-Hispanic Black individuals, with significant increases observed across all demographic groups. The West demonstrated the highest regional mortality burden (AAPC, 3.75%; p < 0.001). Urbanization analyses (2004–2020) showed higher mortality in non-metropolitan than metropolitan areas (AAPCs, 5.36% vs. 4.13%; both p < 0.001). Mortality increased through 2021 before declining modestly during 2021–2024. Conclusions: Mortality involving both cardiac arrest and fluid, electrolyte, and acid–base disorders increased substantially in the United States over the past two decades, with persistent disparities in age, sex, race/ethnicity, and geography. These findings identify populations at increased risk and support targeted public health strategies, equitable healthcare access, and improved recognition and management of metabolic disturbances in patients at risk for cardiac arrest.

12 November 2026 in Journal of Cardiothoracic Surgery
Verified
Journal Article
Open access
PDF file
AIAmr Ibrahim
Amr Ibrahim
AEAlaa El-Deeb
Alaa El-Deeb
RMRaveen Mujeeb
Raveen Mujeeb
AMAlyaa Ahmed Ahmed Ibrahim Mohamed
Alyaa Ahmed Ahmed Ibrahim Mohamed
MEMohamed Elfeki
Mohamed Elfeki
MHMohamed Fawzi Hemida
Mohamed Fawzi Hemida
Introduction: Congenital heart disease remains a leading congenital cause of infant mortality in the United States despite major advances in diagnosis and neonatal care. This study evaluated national mortality trends from 1999 to 2025, examined sex and racial disparities, and projected future burden through 2040 using time-series forecasting. Methods: A retrospective CDC WONDER analysis examined U.S. infant (< 1 year) CHD mortality from 1999 to 2025 using ICD-10 codes Q20–Q26. Deaths listing CHD as underlying or contributing cause were included. Crude mortality rates (CMRs) per 100,000 with 95% CIs were calculated. Trends were evaluated using Joinpoint regression analysis to estimate annual percent change (APC) and average annual percent change (AAPC). Forecasts to 2040 used ARIMA and ETS models, stratified by sex and race/ethnicity. Results: From 1999 to 2025, 55,719 infant deaths related to CHD were recorded in the United States, 92.16% in medical facilities. The CMRs declined from 69.66 in 1999 to 46.44 in 2025 (AAPC − 1.32%) and is projected at 37.51 by 2040. Male mortality remained higher than female (54.86 vs. 52.04). NH Black infants had the highest mean mortality (71.87), while NH Asian/Pacific Islander infants showed the steepest decline (AAPC − 2.30%). Recent increases appeared in NH White infants after 2018 (APC 1.56%) and Hispanic infants after 2020 (APC 3.48%) overall. Conclusion: Infant CHD related mortality declined substantially from 1999 to 2025 and is projected to continue decreasing through 2040; however, persistent excess mortality in male, NH Black, and Hispanic infants underscores enduring demographic disparities in outcomes.

10 November 2026 in Journal of the National Medical Association
Verified
Journal Article
Closed access
PAPalwasha Asghar
Palwasha Asghar
FHFizzah Ikram Ul Haq
Fizzah Ikram Ul Haq
MSMohammad Sameed Safwan
Mohammad Sameed Safwan
AMArchi Mehta
Archi Mehta
SSSafiullah Soomro
Safiullah Soomro
MJMuhammad Hassaan Javaid
Muhammad Hassaan Javaid